Drug-Patent Cliffs
Invest in

Drug-Patent Cliffs

23.8%
10.8%
0.6%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
23.8%
10.8%
0.6%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
67.3% Generic Drugs 14.0%
20.0% Perrigo Co. PRGO 22.2%
12.8% Mylan NV MYL --
8.8% Dr. Reddys Laboratories Ltd. ADS RDY 29.5%
7.1% Taro Pharmaceutical Industries Ltd. TARO 14.9%
4.3% Endo International PLC ENDP 18.1%
3.2% Akorn Inc. AKRX 2.2%
3.1% Mallinckrodt plc MNK 1.7%
2.1% Impax Laboratories Inc. IPXL 65.6%
1.9% Sagent Pharmaceuticals Inc. SGNT 30.4%
1.1% Igi Laboratories Inc IG 22.1%
1.1% Lannett Co. Inc. LCI 48.2%
1.0% Cambrex Corp. CBM 100.4%
0.9% Amphastar Pharmaceuticals Inc (DE) AMPH 11.5%
29.8% Big Pharma 22.7%
22.8% Teva Pharmaceutical Industries TEVA 28.2%
7.0% Abbott Laboratories ABT 5.0%
2.9% Biosimilars 92.3%
1.1% Pfenex Inc PFNX 193.1%
0.9% Momenta Pharmaceuticals Inc. MNTA 56.8%
0.8% Coherus BioSciences Inc CHRS --